Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: A network meta-analysis of placebo-controlled and active-comparator trials

European Journal of Preventive Cardiology

Volumn 20, Issue 4, 2013, Pages 641-657

  Naci, Huseyin ^a   Brugts, Jasper J ^b   Fleurence, Rachael ^c   Tsoi, Bernice ^a   Toor, Harleen ^a   Ades, A E ^d  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Meta analysis; mixed treatment comparison; prevention of coronary heart disease; statins; systematic review

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

META-ANALYSIS; MIXED TREATMENT COMPARISON; PREVENTION OF CORONARY HEART DISEASE; STATINS; SYSTEMATIC REVIEW;

CONTROLLED CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ODDS RATIO; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84880271369     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487313480435     Document Type: Article

References (49)

1. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Archives of Internal Medicine 1999; 15: 1793-1802.
2. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Archives of Internal Medicine. 2004 ; 13: 1427-1436
3. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Journal of the American College of Cardiology. 2006 ; 3: 438-445
4. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Journal of the American Medical Association. 1997 ; 278: 313-321
5. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. Canadian Medical Association Journal. 2008 ; 5: 576-584
6. Miller DB. Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies. Archives of Internal Medicine. 1997 ; 157: 2045-2052
7. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. British Medical Journal. 2003 ; 326: 1423-1423
8. Cheung BM, Lauder IJ, Lau CP, et al. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. British Journal of Clinical Pharmacology. 2004 ; 57: 640-651
9. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366: 1267-1278
10. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. Journal of the American Medical Association. 1999 ; 282: 2340-2346
11. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. Journal of American College of Cardiology. 2008 ; 51: 37-45
12. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. Journals of Gerontology. A Biological Sciences and Medical Sciences. 2007 ; 62: 879-887
13. Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. British Medical Journal. 2006 ; 332: 1115-1124
14. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008 ; 371: 117-125
15. Brugts JJ, Deckers JW. Statin prescription in men and women at cardiovascular risk: to whom and when?. Current Opinion in Cardiology. 2010 ; 25: 484-489
16. Minder CM, Blaha MJ, Tam LM, et al. Making the case for selective use of statins in the primary prevention setting. Archives of Internal Medicine. 2011 ; 171: 1593-1594
17. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. British Medical Journal. 2009 ; 338: b2376 - b2376
18. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Archives of Internal Medicine. 2010 ; 170: 1024-1031
19. Taylor F, Ward K, Moore Theresa HM, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2011; (1): CD004816.
20. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable?. Lancet. 1999 ; 354: 1202-1204
21. Mills EJ, WU P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170‚ 255 patients from 76 randomized trials. QJM. 2011 ; 104: 109-124
22. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. Journal of American College of Cardiology. 2008 ; 52: 1769-1781
23. Alberton M, Wu P, Druyts E, et al. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM. 2012 ; 105: 145-157
24. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. American Heart Journal. 2006 ; 151: 273-281
25. Naci H, Brugts J, Fleurence R, et al. Comparative efficacy and safety of statins: a systematic review and mixed treatment comparison. London: London School of Economics & Political Science. Available at: www2.lse.ac.uk/ LSEHealthAndSocialCare/pdf/HNaciProtocol.pdf (2009, accessed December 2011).
26. Borenstein M, Hedges LV, Higgins JPT, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Research Synthesis Methods. 2010 ; 1: 97-111
27. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal. 2005 ; 331: 897-900
28. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value in Health. 2011 ; 14: 417-428
29. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine. 2004 ; 23: 3105-3124
30. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology. 2011 ; 64: 163-171
31. Song F, Xiong T, Parekh-Bhurke S, et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. British Medical Journal 2011;343.
32. Dias S, Welton NJ, Sutton AJ, et al. NICE DSU technical support document 1: introduction to evidence synthesis for decision making - report by the decision support unit. London: NICE. Available at: http://www.nicedsu.org.uk (2011, accessed December 2011).
33. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Journal of American College of Cardiology. 2006 ; 48: 438-445
34. The Post Coronary Artery Bypass Graft Trial Investigators. New England Journal of Medicine. 1997 ; 336: 153-162
35. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Annals of Internal Medicine. 1993 ; 119: 969-976
36. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. New England Journal of Medicine. 1994 ; 331: 1331-1337
37. Sahni R, Maniet AR, Voci G, et al. Prevention of restenosis by lovastatin after successful coronary angioplasty. American Heart Journal. 1991 ; 121 (6 Pt 1). 1600-1608
38. Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. Journal of the American Medical Association. 2007 ; 297: 1344-1353
39. Stein EA, Strutt K, Southworth H, et al. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. American Journal of Cardiology. 2003 ; 92: 1287-1293
40. Leiter LA, Rosenson RS, Stein E, et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis. 2007 ; 194: e154 - e164
41. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. Journal of the American Medical Association. 2002 ; 287: 3215-3222
42. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis. 1999 ; 144: 263-270
43. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. European Heart Journal. 1999 ; 20: 58-69
44. Stone PH, Lloyd-Jones DM, Kinlay S, et al. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study. Circulation. 2005 ; 111: 1747-1755
45. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine. 2006 ; 355: 549-559
46. Corsini A. Fluvastatin: effects beyond cholesterol lowering. Journal of Cardiovascular Pharmacology and Therapy. 2000 ; 5: 161-175
47. Hopewell S, Dutton S, Yu L-M, et al. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. British Medical Journal. 2010 ; 340: c723 - c723
48. Jansen JP, Schmid CH, Salanti G. Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons. Journal of Clinical Epidemiology. 2012 ; 65: 798-807
49. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 ; 376: 1670-1681